RNS : FOR IMMEDIATE RELEASE |
|
TR1 NOTIFICATION OF MAJOR INTEREST BY AVIVA
Full disclosure of the TR1 is shown below:
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
|
|
|
|||
1. Identity of the issuer or the underlying issuer |
|
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
√ |
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
√ |
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): |
|
|
||
3. Full name of person(s) subject to the |
|
|||
4. Full name of shareholder(s) |
Registered Holder:
Chase (
*denotes direct interest
Chase (
|
|||
5. Date of the transaction and date on |
|
|||
6. Date on which issuer notified: |
|
|||
7. Threshold(s) that is/are crossed or |
7% to 8% Change at Direct Interest Level |
|||
8. Notified details: |
||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
||||||
Ordinary Shares
GB0033711010 |
11,332,848* |
11,332,848* |
11,285,180 |
9,820,195 |
1,464,985 |
8.06% |
1.21% |
|||
|
||||||||||
* Includes right to recall loaned shares (100,000)
|
||||||||||
B: Qualifying Financial Instruments |
||||||||||
Resulting situation after the triggering transaction |
||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||
|
|
|
|
|
||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||
Resulting situation after the triggering transaction |
||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|
|
|
|
|
|
|
|
|
|
Total (A+B+C) |
|
Number of voting rights |
Percentage of voting rights |
11,285,180 |
9.27% |
9. Chain of controlled undertakings through which the voting rights and/or the |
||
The voting rights are managed and controlled by
· · · ·
|
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
See Section 4 |
|
11. Number of voting rights proxy holder will cease to hold: |
|
|
12. Date on which proxy holder will cease to hold |
|
|
|
||
|
|
|
14. Contact name: |
Neil Whittaker, |
|
15. Contact telephone number: |
01603 684420 |
|
-Ends-
For further information please contact:
|
|
Notes to Editors
ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the
ImmuPharma announced on
LupuzorTM
LupuzorTM (also referred to as forigerimod, rigerimod, IPP-201101 or P140 is ImmuPharma's lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. LupuzorTM has a novel mechanism of action aimed at modulating the body's immune system so that it does not attack healthy cells, and avoids causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.
LupuzorTM has been granted Fast Track status by the US FDA and approval to start Phase III under Special Protocol Assessment (SPA). This SPA was subsequently amended due to its strong safety and efficacy profile to allow for a reduced number of patients in the pivotal Phase III trial thereby reducing the projected cost and time of development considerably.
The pivotal Phase III clinical study is entitled "A 52-Week, Randomized, Double-Blind,
Commercial Opportunity
There are an estimated five million people globally suffering from Lupus, with approximately 1.5 million patients in the US, Europe and Japan (Source:
This information is provided by RNS